arXiv · 2001.10573
Study of dose-dependent combination immunotherapy using engineered T cells and IL-2 in cervical cancer
Abstract
Adoptive T cell based immunotherapy is gaining significant traction in cancer treatment. Despite its limited success, so far, in treating solid cancers, it is increasingly successful, demonstrating to have a broader therapeutic potential. In this paper we develop a mathematical model to study the efficacy of engineered T cell receptor (TCR) T cell therapy targeting the E7 antigen in cervical cancer cell lines. We consider a dynamical system that follows the population of cancer cells, TCR T cells, and IL-2. We demonstrate that there exists a TCR T cell dosage window for a successful cancer elimination that can be expressed in terms of the initial tumor size. We obtain the TCR T cell dose for two cervical cancer cell lines: 4050 and CaSki. Finally, a combination therapy of TCR T cell and IL-2 treatment is studied. We show that certain treatment protocols can improve therapy responses in the 4050 cell line, but not in the CaSki cell line.
Explore related subjects
Keep this discovery
Heyrim Cho, Zuping Wang, Doron Levy. 2020-01-28. Study of dose-dependent combination immunotherapy using engineered T cells and IL-2 in cervical cancer. https://doi.org/10.1016/j.jtbi.2020.110403
Cite the original work for its findings. Save a collection to share your selection of sources.